167 related articles for article (PubMed ID: 18953273)
1. New protease inhibitors and non-nucleoside reverse transcriptase inhibitors.
Lascar M; Cartledge JD
J HIV Ther; 2008 Jun; 13(2):40-4. PubMed ID: 18953273
[No Abstract] [Full Text] [Related]
2. Drugs in traditional drug classes (nucleoside reverse transcriptase inhibitor/nonnucleoside reverse transcriptase inhibitor/protease inhibitors) with activity against drug-resistant virus (tipranavir, darunavir, etravirine).
Arribas JR
Curr Opin HIV AIDS; 2009 Nov; 4(6):507-12. PubMed ID: 20048718
[TBL] [Abstract][Full Text] [Related]
3. Protease inhibitors: the current status.
Dauer B
J HIV Ther; 2005 Dec; 10(4):72-4. PubMed ID: 16519246
[No Abstract] [Full Text] [Related]
4. Relative antiviral efficacy should not be inferred from cross-trial comparisons.
Hall D
HIV Med; 2007 Nov; 8(8):570-1; author reply 571-2. PubMed ID: 17944692
[No Abstract] [Full Text] [Related]
5. [Position of darunavir in antiretroviral therapy].
Clotet B
Enferm Infecc Microbiol Clin; 2008 Oct; 26 Suppl 10():61-2. PubMed ID: 19195461
[No Abstract] [Full Text] [Related]
6. New treatment options for HIV salvage patients: an overview of second generation PIs, NNRTIs, integrase inhibitors and CCR5 antagonists.
Hughes A; Barber T; Nelson M
J Infect; 2008 Jul; 57(1):1-10. PubMed ID: 18556070
[TBL] [Abstract][Full Text] [Related]
7. Trial of tipranavir versus darunavir in treatment-experienced patients enrolling.
AIDS Patient Care STDS; 2007 Aug; 21(8):6-3. PubMed ID: 17902242
[No Abstract] [Full Text] [Related]
8. A lame duck, a dark horse, and a goat.
Huff B
GMHC Treat Issues; 2005; 19(5-6):4-5. PubMed ID: 16193576
[No Abstract] [Full Text] [Related]
9. Relative antiviral efficacy of ritonavir-boosted darunavir and ritonavir-boosted tipranavir vs. control protease inhibitor in the POWER and RESIST trials.
Hill A; Moyle G
HIV Med; 2007 May; 8(4):259-64. PubMed ID: 17461854
[TBL] [Abstract][Full Text] [Related]
10. Darunavir.
El-Atrouni WI; Temesgen Z
Drugs Today (Barc); 2007 Oct; 43(10):671-9. PubMed ID: 17987220
[TBL] [Abstract][Full Text] [Related]
11. [Tipranavir: therapeutic drug monitoring in a pediatric patient with HIV infection].
Soler-Palacín P; Fàbrega A; María López R; Figueras C
Enferm Infecc Microbiol Clin; 2009 Feb; 27(2):133-4. PubMed ID: 19254645
[No Abstract] [Full Text] [Related]
12. [New therapeutic options in protracted HIV-infected patients with virological failure].
Moreno Cuerda VJ; Rubio García R; Morales Conejo M
Med Clin (Barc); 2008 Jan; 130(2):66-70. PubMed ID: 18221677
[TBL] [Abstract][Full Text] [Related]
13. Activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV Type 1: results of a phase 2, randomized, controlled, dose-ranging clinical trial.
Zolopa AR; Berger DS; Lampiris H; Zhong L; Chuck SL; Enejosa JV; Kearney BP; Cheng AK
J Infect Dis; 2010 Mar; 201(6):814-22. PubMed ID: 20146631
[TBL] [Abstract][Full Text] [Related]
14. Drug resistance mutations in HIV-infected patients in the Spanish drug resistance database failing tipranavir and darunavir therapy.
Poveda E; Anta L; Blanco JL; Casado JL; Gutiérrez F; García F; Gómez-Sirvent JL; Iribarren JA; Soriano V; de Mendoza C;
Antimicrob Agents Chemother; 2010 Jul; 54(7):3018-20. PubMed ID: 20479204
[TBL] [Abstract][Full Text] [Related]
15. Evidence for different susceptibility to tipranavir and darunavir in patients infected with distinct HIV-1 subtypes.
Poveda E; de Mendoza C; Parkin N; Choe S; García-Gasco P; Corral A; Soriano V
AIDS; 2008 Mar; 22(5):611-6. PubMed ID: 18317002
[TBL] [Abstract][Full Text] [Related]
16. Successful use of a tipranavir/ritonavir-based antiretroviral regimen following development of viral resistance to darunavir.
Pierone G; Urban T; Martin A; Mieras J; Kantor C
HIV Clin Trials; 2008; 9(2):140-1. PubMed ID: 18474499
[No Abstract] [Full Text] [Related]
17. New drugs.
Waters L; Nelson MR
HIV Med; 2005 Jul; 6(4):225-31. PubMed ID: 16011526
[No Abstract] [Full Text] [Related]
18. Some existing drugs work on resistant HIV.
AIDS Alert; 2000 Jan; 15(1):10-2. PubMed ID: 11366357
[TBL] [Abstract][Full Text] [Related]
19. Short communication: Phenotypic protease inhibitor resistance and cross-resistance in the clinic from 2006 to 2008 and mutational prevalences in HIV from patients with discordant tipranavir and darunavir susceptibility phenotypes.
Bethell R; Scherer J; Witvrouw M; Paquet A; Coakley E; Hall D
AIDS Res Hum Retroviruses; 2012 Sep; 28(9):1019-24. PubMed ID: 22098079
[TBL] [Abstract][Full Text] [Related]
20. Different evidence of key amprenavir resistance mutations on the efficacy of darunavir.
Di Biagio A; Rosso R; Bruzzone B; Cenderello G; Dentone C; Mularoni A; Ferrea G; Icardi G; Viscoli C
AIDS; 2008 Jan; 22(3):437-8. PubMed ID: 18195574
[No Abstract] [Full Text] [Related]
[Next] [New Search]
